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Toward Personalized Medicine: Using Cardiomyocytes Differentiated
From Urine-Derived Pluripotent Stem Cells to Recapitulate
Electrophysiological Characteristics of Type 2 Long QT Syndrome
Mariam Jouni, MSc;* Karim Si-Tayeb, PhD;* Zeineb Es-Salah-Lamoureux, PhD; Xenia Latypova, MSc; Benoite Champon, BSc;
Amandine Caillaud, PhD; Anais Rungoat, MSc; Flavien Charpentier, PhD; Gildas Loussouarn, PhD; Isabelle Baro, PhD; Kazem Zibara, PhD;
Patricia Lemarchand, MD, PhD; Nathalie Gaborit, PhD
Background-—Human genetically inherited cardiac diseases have been studied mainly in heterologous systems or animal models,
independent of patients’ genetic backgrounds. Because sources of human cardiomyocytes (CMs) are extremely limited, the use of
urine samples to generate induced pluripotent stem cell–derived CMs would be a noninvasive method to identify cardiac
dysfunctions that lead to pathologies within patients’ speciﬁc genetic backgrounds. The objective was to validate the use of CMs
differentiated from urine-derived human induced pluripotent stem (UhiPS) cells as a new cellular model for studying patients’
speciﬁc arrhythmia mechanisms.
Methods and Results-—Cells obtained from urine samples of a patient with long QT syndrome who harbored the HERG A561P
gene mutation and his asymptomatic noncarrier mother were reprogrammed using the episomal-based method. UhiPS cells were
then differentiated into CMs using the matrix sandwich method. UhiPS-CMs showed proper expression of atrial and ventricular
myoﬁlament proteins and ion channels. They were electrically functional, with nodal-, atrial- and ventricular-like action potentials
recorded using high-throughput optical and patch-clamp techniques. Comparison of HERG expression from the patient’s UhiPS-
CMs to the mother’s UhiPS-CMs showed that the mutation led to a trafﬁcking defect that resulted in reduced delayed rectiﬁer K+
current (IKr). This phenotype gave rise to action potential prolongation and arrhythmias.
Conclusions-—UhiPS cells from patients carrying ion channel mutations can be used as novel tools to differentiate functional CMs
that recapitulate cardiac arrhythmia phenotypes. ( J Am Heart Assoc. 2015;4:e002159 doi: 10.1161/JAHA.115.002159)
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D espite important achievements in the understanding ofcardiovascular diseases over the past decade, heart
disease remains the principal cause of death in developed
societies. Intense research efforts have been directed at using
human induced pluripotent stem (hiPS) cells to invoke cardiac
regeneration for heart repair and to model human cardiac
development and diseases in vitro. Recent studies have
demonstrated that hiPS cell–derived cardiomyocytes (CMs)
can be used to model several human genetically inherited
cardiac diseases that manifest defects in speciﬁc cardiac
structural components, signaling pathways, or electrophysio-
logical properties1, validating the technique as a powerful
system with which to gain mechanistic insights into human
cardiac disease. Currently, a wide variety of molecular,
cellular, and physiological assays are optimized to investigate
disease phenotypes in hiPS cell–derived CMs. Experimental
drugs have also been tested in this setting, inducing
alleviation of the disease phenotypes and further paving the
way for new therapeutic interventions for cardiac diseases.
Importantly, as recently developed by Yamanaka, iPS cell
technology can contribute to micromedicine (eg, applied to an
individual patient) and personalized medicine, including drug
discovery based on cellular and molecular analyses.2 It may
also contribute in the future to macromedicine (eg, applied to
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cohorts of patients), including patient stratiﬁcation, based on
cellular and molecular analyses of participants in clinical trials
or cohort studies.2
Nevertheless, the standard approach by which hiPS cells
are generated from skin biopsy as raw material limits the
extensive use of this technology. Skin biopsy requires an
invasive procedure, accompanied by discomfort and risk of
bleeding, infection, and permanent scars. Skin biopsy collec-
tion also raises ethical issues in the case of young children
and patients’ healthy relatives. Furthermore, the obtained
cells expand slowly in culture, and the reprogramming
efﬁcacy is low. This may require several skin samples;
however, the procedure cannot easily be performed several
times on the same person. There is a growing consensus that
an ideal source for hiPS cells should provide cells easily and
noninvasively, with high reprogramming efﬁcacy. Progress
has been made regarding this issue with the reprogramming
of cells from blood samples, but there is still room for
improvement.
Recent reports showed that cells contained in a simple
urine sample can be an easy and noninvasive source for
generating hiPS cells.3–6 Reprogramming efﬁcacy of urine-
derived cells is higher than for human dermal ﬁbroblasts:
Efﬁcacy for both viral and nonintegrative methods was
consistently higher in urine cells compared with dermal cells,
including retroviral reprogramming that was 50 times more
efﬁcient in urine cells3,7–9 and episomal reprogramming that
was 10 times more efﬁcient.4,10,11 Furthermore, the cardiac
molecular phenotype of a dystrophin-deﬁcient patient was
recapitulated in CMs derived from the patient’s urine cells.12
Producing urine-derived CMs from patients with genetic
disorders and from their healthy relatives can facilitate study
of the impact of individual genetic variation on the risk and
progression of the disease of interest.
In the present study, starting from a urine sample, we
developed an in vitro model for a patient suffering from a mild
form of type 2 long QT (LQT2) syndrome. The long QT
syndrome is an inherited cardiac channelopathy that causes
potentially fatal cardiac arrhythmia and was one of the ﬁrst
successfully modeled human diseases using hiPS cells.1,13 We
investigated the mutation A561P located in the KCNH2 gene
encoding the HERG channel. This mutation was the focus of
an initial study conducted in the laboratory.14 The patient
harboring this mutation presented arrhythmias only when
treated with clobutinol, an antitussive drug. Due to the lack of
a cardiac cellular model, the analyses were performed in
transfected COS-7 cells, and the overall effects on cardiac
action potential (AP) were extrapolated with an in silico
analysis. In the present study, we used CMs obtained from
urine-derived hiPS cells (UhiPS-CMs) to investigate both the
molecular and functional phenotypes of the syndrome in a
native cellular model. We observed AP changes, characteristic
for the long QT syndrome, that were exacerbated by a HERG
inhibitor, thus modeling the patient-speciﬁc arrhythmic drug
sensitivity. We demonstrated that the use of UhiPS-CMs is a
convenient and powerful approach to ﬁnely model human
arrhythmic diseases.
Methods
Patient Characteristics
The study was conducted in compliance with current good
clinical practice standards and in accordance with the
principles set forth under the Declaration of Helsinki (1989).
Institutional review board approvals of the study were
obtained before initiation of patient enrollment. Each partic-
ipant entering the study agreed to and signed an institutional
review board–approved statement of informed consent.
Somatic cells from a urine sample were obtained from a
man aged 22 years who presented syncope and torsades de
pointes arrhythmia at age 13 years during treatment with the
antitussive drug clobutinol.14 ECG analysis showed prolonged
QT duration (corrected QT interval of 628 ms with Bazett’s
formula and 597 ms with Fredericia’s formula). The patient
carries a missense mutation in the KCNH2 gene, encoding the
HERG K+ channel a-subunit, causing an alanine-to-proline
substitution at position 561 (chromosome 7: 150 648 800G>
C; NM_000238 A561P). As a control, somatic cells from a
urine sample were also obtained from the patient’s mother,
aged 46 years, who had no clinical symptoms and a normal
ECG and who was negative for the KCNH2 mutation. An
additional control, the previously described foreskin ﬁbrob-
last-derived hiPS (FhiPS) cell clone iPS.C2a, was also
used.15
Urine Cell Collection, Isolation, and Culture
Urine cells were isolated and cultured, as described
previously.3 Brieﬂy, cell pellets were collected from whole
urine samples (130 to 265 mL) via centrifugation (5 min-
utes at 1200g) and washed with PBS. Pellets were
resuspended in RE/MC (renal epithelial/mesenchymal cell)
medium composed of 50% RE medium (renal epithelial cell
growth medium SingleQuot supplement and growth factors
[catalog number CC-3190; Lonza]) and 50% MC medium
(DMEM/high glucose supplemented with 10% [vol/vol] FBS,
1% [vol/vol] GlutaMAX, 1% [vol/vol] nonessential amino
acid [NEAA], 100 U/mL penicillin, 100 lg/mL strepto-
mycin, 5 ng/mL basic ﬁbroblast growth factor [Miltenyi
Biotec], 5 ng/mL PDGF-AB [Cell Guidance] and 5 ng/mL
epidermal growth factor [PeproTech]) and cultured on 0.1%
gelatin-coated plates. Urine cell clusters were passaged
using TripLE (Life Technologies) and characterized.
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Urine Cell Reprogramming and UhiPS Cell
Characterization
Urine cells were reprogrammed into UhiPS cells, as described
previously.6 Brieﬂy, 39105 to 59105 urine cells were
nucleofected (Lonza) with episomal vectors coding for
OCT3/4, SOX2, KLF4, MYC, LIN28, NANOG, and SV40LT
(catalog numbers 20922, 20923, 20924, 20925, and 20927;
Addgene), and a nonepisomal vector coding for miR302/367
(catalog number TDH101PA-GP; System Biosciences) and
cultured 14 to 21 days with E7 medium (Stemcell Technolo-
gies). UhiPS clones were manually picked on mouse embry-
onic ﬁbroblasts (MEFs). Control UhiPS and A561P-UhiPS cells
were characterized by reverse transcription polymerase chain
reaction to verify the expression of endogenous pluripotent
factors OCT3/4, NANOG, and SOX2 and the loss of episomal
vectors; immunostaining; ﬂow cytometry; and the ability to
form teratoma.
Flow Cytometry Analysis
A total of 19105 cells in suspension for each condition were
washed 3 times with PBS/BSA 0.1% and then incubated
with phycoerythrin (PE)-labeled antibodies SSEA3-PE, SSEA4-
PE, and TRA1-60-PE (eBioscience) for 30 minutes at 4°C in the
dark and further rinsed 3 times with ﬂuorescence-activated cell
sorting buffer. Data acquisition was performed using FACSDiva
software with an LSR II instrument (Becton Dickinson) or the
Accury C6 (Becton Dickinson).
Episomal Vector Detection
Total RNA was extracted from hiPS cells at passage 10 using
the RNeasy Mini Kit (Qiagen). Following the manufacturer’s
instructions, 1 µg of total RNA was reverse transcribed using
the High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Reverse transcription polymerase chain reaction
studies were conducted in triplicate using Mesa Green 2X
PCR Master Mix for SYBR (Eurogentec). DNA concentration
was 5 ng per well. Conditions were 2 seconds at 90°C,
followed by 40 cycles of 10 seconds at 95°C and 30 seconds
at 60°C, and ending by 60 seconds at 60°C. Cycle threshold
was calculated using default settings for the real-time
sequence detection software (Applied Biosystems). Primer
sequences are listed in Table S1.
Teratoma Formation
Undifferentiated UhiPS cells cultured on MEFs were mechan-
ically dissociated with EZ Passage tools (Life Technologies),
resuspended in Matrigel (2 mg/mL; Corning), and injected
subcutaneously into NOD/SCID IL2R-c mice (Charles River).
Tumor samples were collected after 8 to 10 weeks, ﬁxed in
4% paraformaldehyde, embedded in parafﬁn, sectioned, and
stained with hematoxylin and eosin for analysis. The animal
experiments were approved by the regional ethics commitee
and the ministry of national education (protocol 02017.01).
Culture of hiPS Cells
Established hiPS cell lines were maintained on mitotically
inactivated MEFs in DMEM/F12 medium supplemented with
2 mmol/L L-glutamine, 0.07% b-mercaptoethanol, 20% knock-
out serum replacement, 5 ng/mL basic ﬁbroblast growth
factor, and 1% NEAA in a low-oxygen atmosphere (4% O2).
Cells were passaged by manual dissection of cell clusters
every 6 to 7 days. Before differentiation, hiPS cells were
manually transferred from MEFs to Matrigel-coated plates
(0.05 mg/mL; BD Biosciences) and cultured on mTeSR1
medium (Stemcell Technologies). Passages were performed
using Gentle Cell Dissociation Buffer (Stemcell Technologies).
Differentiation of hiPS Cells Into CMs and
Dissociation
Human iPS cells were differentiated into CMs using the
established matrix sandwich method16 with modiﬁcations.
Brieﬂy, 6 days before initiating differentiation, hiPS cell
colonies were passaged on human embryonic stem cell–
qualiﬁed Matrigel-coated plates (0.05 mg/mL; BD Bio-
sciences) using Gentle Cell Dissociation Buffer (Stemcell
Technologies) and cultured as a monolayer in mTeSR1 with
19 Y-27632 ROCK inhibitor (Stemcell Technologies) in a
normal oxygen atmosphere. When cells reached 80% conﬂu-
ence, cold mTeSR1 with Growth Factor Reduced Matrigel
(0.033 mg/mL) was added to create an overlay of Matrigel.
Differentiation was initiated 24 hours later (day 0) by
culturing the cells in RPMI-1640 medium (Life Technologies)
supplemented with B27 (without insulin; Life Technologies),
100 ng/mL activin A (Miltenyi Biotec), and 10 ng/mL FGF2
(Miltenyi Biotec) for 24 hours. On the next day, the medium
was replaced by RPMI-1640 medium supplemented with B27
without insulin, 10 ng/mL BMP4 (Miltenyi Biotec), and 5 ng/mL
FGF2 for 4 days. By day 5, cells were cultured in RPMI-1640
medium supplemented with B27 complete (Life Technologies)
and 1% NEAA and changed every 2 to 3 days.
For protein and electrophysiological analyses, CMs were
dissociated around day 20 of differentiation by 20-minute
incubation with collagenase II (200 U/mL; Gibco) and 0.2 U/mL
protease XIV (Sigma-Aldrich) at 37°C. Isolated cells were then
incubated at room temperature for 30 minutes in Kraft–Bruhe
solution containing 85 mmol/L KCl, 30 mmol/L K2HPO4,
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5 mmol/L MgSO4, 1 mmol/L EGTA, 2 mmol/L Na2-ATP,
5 mmol/L Na-pyruvate, 5 mmol/L creatinine, 20 mmol/L
taurine, and 20 mmol/L glucose (pH 7.2).17
Gene Expression Analysis
Total RNA was extracted from hiPS colonies or during
differentiation at days 5, 18, and 28 using the RNeasy Mini
Kit (Qiagen). Following the manufacturer’s instructions, 1 lg
of total RNA was reverse transcribed using the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). Poly-
merase chain reaction ampliﬁcation was performed using
FAM-labeled TaqMan probes (Applied Biosystems) (Table S1).
Protein Expression Analysis
For histological analysis, 2 cell types were analyzed: Type 1
comprised undifferentiated UhiPS cells, which were cultured
in 12-well plates on MEF feeders, and type 2 comprised
dissociated hiPS-derived CMs, which were plated on Ibidi
plates (Biovalley) and further cultured for 6 to 10 days. For
type 1 cells, UhiPS cells on MEFs were ﬁxed with 4%
paraformaldehyde, permeabilized with 0.5% Triton X-100, and
blocked with 3% PBS-BSA. Cells were then stained with
primary antibodies directed against OCT3/4 (Santa Cruz
Biotechnology) and TRA1-60 (eBioscience) diluted in 1%
PBS-BSA. For type 2 cells, after methanol ﬁxation, cells were
permeabilized with 0.1% Triton X-100, blocked with 5%
PBS-BSA and stained with primary antibodies against
a-actinin (Abcam), troponin I (Santa Cruz Biotechnology),
MLC2a (Abcam), MLC2v (Proteintech Europe), connexin 43
(Chemicon), HERG (Santa Cruz Biotechnology), or Nav1.5
(Alomone Labs). Secondary antibody staining was performed
using Alexa 488– and Alexa 568–conjugated antibodies
(Molecular Probes). DAPI was used for nuclear staining.
For Western blot analysis, 40 lg of protein lysate from
UhiPS-CMs were incubated with antisera against HERG (Santa
Cruz Biotechnology) protein. Secondary antibody staining was
performed using goat anti-mouse IgG-HRP antibody (Santa
Cruz Biotechnology). Stain Free gel technology (Bio-Rad) was
used as a loading control for protein normalization.18,19 The
amount of total proteins in each lane on the blot was
calculated and used for normalization.
Cellular Electrophysiology
AP optical recordings were performed on CMs after 28 days
of differentiation, with 5 lmol/L di-8-ANEPPS (Life Technolo-
gies) as the voltage-sensitive dye, using the CellOptiq
technology (Clyde Biosciences). Cells were incubated at
37°C, 5% CO2, and 20% O2 during the 2-hour incubation of
the dye and during the recording.
Dissociated hiPS-derived CMs were resuspended in RPMI
plus B27 supplemented with insulin and 1% NEAA and then
plated on Matrigel-coated 35-mm plastic Petri dishes. Isolated
beating cells were used for patch-clamp recordings using
whole-cell conﬁgurations between days 10 and 14 after
dissociation. The rapid component of the delayed rectiﬁer K+
current (IKr) and APs were recorded in the ruptured and
permeabilized patch-clamp conﬁgurations, respectively. Cells
were continuously superfused with a Tyrode solution contain-
ing (in mmol/L): NaCl 140, KCl 4, CaCl2 1, MgCl2 1, glucose
10, HEPES 10; pH 7.4 (NaOH). During recording, a local
gravity microperfusion system allowed application of drugs,
dissolved in Tyrode solution in which glucose was replaced by
mannitol 20 mmol/L.20 For AP recording, the pipette solution
contained (in mmol/L): K-gluconate 125, KCl 20, NaCl 5,
amphotericin B 0.85, HEPES 10; pH 7.2 (KOH). For IKr
recording, the pipette was ﬁlled with a solution containing (in
mmol/L): K-gluconate 125, KCl 20, K2ATP 5, HEPES 10, EGTA
10; pH 7.2 (KOH).21 All products were purchased from
Sigma-Aldrich. Data were recorded through an A/D con-
verter (Digidata 1440A; Molecular Devices) using an
Axopatch 200B ampliﬁer (Molecular Devices). Membrane
currents and APs were analyzed with an Axon pClamp 10
(Molecular Devices). Borosilicate patch pipettes had a tip
resistance of 2 to 2.5 MΩ. All experiments were made at
352°C. During voltage-clamp experiments, nifedipine
(4 lmol/L) was added to the external solution to block
the L-type calcium current (ICa,L). IKr was measured as a 1-
lmol/L E-4031-sensitive current by digitally subtracting the
current in the presence of E-4031 from that in its absence.
IKr densities were calculated by dividing current amplitude,
measured at the peak of the tail current at 50 mV
following depolarization to 60 mV (prepulse), by cell mem-
brane capacitance. Activation curves, determined from peak
tail current normalized to the maximal value and plotted
against the prepulse voltage, were ﬁtted with a single
Boltzmann function, G/Gmax=1/(1+exp[(V1/2V)/k]), in
which G/Gmax is the conductance normalized with respect
to the maximal conductance, V1/2 is half activation potential,
V is the prepulse voltage prior to the tail current measure-
ment, and k is the slope factor. Data extracted from this
equation are presented as meanSEM. Statistical signiﬁ-
cance of differences in current densities or activation
properties was calculated using the Student t test.
Statistical Analysis
Data are expressed as meanSEM. Statistical analysis was
performed with Prism 5 (GraphPad Software, Inc). Signiﬁcant
differences between mean values were determined with the
Mann–Whitney U test for comparison of 2 groups or paired
Student t test if appropriate. For more than 2 groups, 2-way
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ANOVA was performed. A P value <0.05 was considered to
indicate signiﬁcance.
Results
Generation of Patient-Speciﬁc hiPS Cells From a
Urine Sample Using Episomal-Based
Reprogramming
Cells isolated from urine samples from the patient carrying
the HERG A561P mutation and from his healthy mother
displayed a mesenchymal stem cell phenotype, including
spindle-shaped morphology and expression of cell surface
markers CD49a, CD73, CD90, CD105, and CD146. They did
not express the hematopoietic stem cell markers CD14,
CD45, and CD184 (data not shown). Cells were repro-
grammed on transfection of episomal vectors. Control UhiPS
clones and A561P-UhiPS clones carrying the A561P mutation
were manually picked for further characterization. Endoge-
nous expression of the pluripotent stem cell markers OCT3/4,
SOX2, and NANOG, absent in the urine cells, was detected by
quantitative reverse transcription polymerase chain reaction
in both UhiPS cells types, and the loss of episomal vector
expression was veriﬁed (Figure S1B). Endogenous expression
of OCT3/4 and TRA1-60 proteins was also visualized by
immunoﬂuorescence staining in control and A561P-UhiPS
cells (Figure S1A). Flow cytometry analysis showed that >90%
of control and A561P-UhiPS cells were positive for the
expression of pluripotency markers TRA1-60, SSEA4, and
SSEA3 (Figure S1C). Finally, the ability of UhiPS cells to form
teratoma with all 3 germ layers was observed (Figure S1D).
Urine cells were successfully reprogrammed into bona ﬁde
hiPS cells, and 2 to 3 clones per line were selected to perform
the following experiments.
UhiPS Cells Can Be Differentiated Into Functional
CMs
Using the matrix sandwich method, CMs were differentiated
(1) from control hiPS cells derived from foreskin ﬁbroblasts
(FhiPS-CMs), a reference tissue source that has previously
been used successfully for differentiation into functional
CMs22,23, and from hiPS cells derived from urine samples; (2)
from the control healthy mother’s cells (control UhiPS-CMs);
and (3) from the HERG A561P-mutated cells (A561P-UhiPS
CMs). All 3 hiPS cells showed comparable cardiac differen-
tiation potential (Figure 1), giving rise to spontaneously
contracting cell areas after 6 to 8 days of differentiation.
Gene expression proﬁling of the 3 hiPS cells revealed a similar
differentiation pattern into cardiac cells over time, including
signiﬁcant reduction of pluripotent stem cell markers OCT3/
4, NANOG, and SOX2, and progressive upregulation of a
cardiac transcription factor, NKX2-5; connexins (GJA1 and
GJA5); and a regulator of calcium homeostasis, RYR2, by day
18 (Figure 1A). Similar gene expression proﬁles were also
observed for SCN5A, CACNA1C, CACNA1G, KCND3, KCNQ1,
KCNH2, and KCNJ2, the genes encoding the major cardiac ion
channel a-subunits. We also analyzed the protein expression
patterns of several structural and functional proteins that
characterize CMs, using immunoﬂuorescence on cells isolated
after 30 days of differentiation (Figure 1B). CMs displayed
organized cross-striations, resembling sarcomeres with
proper alignment of the myoﬁbrils, that were positive for
cardiac and muscle-speciﬁc cytoskeletal proteins troponin I,
a-actinin, ventricular myosin light chain (MLC2V), and atrial
myosin light chain (MLC2A). The sodium channel Nav1.5,
responsible for the AP upstroke in atrial, Purkinje, and
ventricular CMs, was properly addressed at the plasma
membrane (data not shown). Finally, dual staining of troponin
I and connexin 43, essential for coordinated cell depolariza-
tion, showed that the transmembrane proteins were located,
as expected, in contact areas between CMs (Figure 1B).
These results show that UhiPS cells could be differentiated
into CMs using the matrix sandwich method.
CMs Differentiated From UhiPS Cells Are
Electrically Functional
APs of the differentiated CMs were assessed using both
patch-clamp and optical recording with the voltage-sensitive
dye di-8-ANEPPS. Isolated CMs derived from both FhiPS and
UhiPS cells started beating by day 6 after dissociation. Using
the patch-clamp technique, spontaneous APs from control
and A561P-UhiPS CMs were recorded and classiﬁed as
nodal-, atrial-, and ventricular-like APs based on their duration,
maximum upstroke velocity (dV/dtmax), peak-to-peak dura-
tion, and maximum diastolic potential (Figure 2A, Table S2).
The 3 types of APs were also obtained during CellOptiq AP
optical recordings (Figure 2B), and their quantiﬁcation
showed that, regardless of hiPS cell origin and genotype,
ventricular-like APs were the most frequently recorded
(Figure 2C). Inversely, nodal-like APs were less frequently
recorded, with none observed in A561P-UhiPS CMs using
patch-clamp technique (Figure 2A).
A561P KCNH2 Mutation Causes a Trafﬁcking
Defect of the HERG Channel in Human CMs
We next investigated whether we could model and charac-
terize the LQT2 syndrome molecular phenotype using UhiPS-
CMs. The A561P mutation studied in COS-7 cells induced a
decrease in plasma membrane expression of the channel that
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potentially causes the disease phenotype.14 We initially
examined cellular localization of HERG by immunoﬂuores-
cence in UhiPS-CMs. As compared with control FhiPS- and
UhiPS-CMs, HERG plasma membrane expression was reduced
in A561P-UhiPS CMs (Figure 3A). Higher magniﬁcation anal-
yses conﬁrmed that in both FhiPS-CMs and UhiPS-CMs, HERG
staining was prominently observed at the cell plasma
membrane (Figure 3B, arrows and plot proﬁles). In contrast,
HERG A561P protein was detected at the plasma membrane
at the same intensity as in intracellular compartments
Figure 1. Human UhiPS cells differentiated into functional cardiomyocytes. A, Transcriptional proﬁle of control hiPS cells derived from skin
ﬁbroblasts (control FhiPS-CMs) and from urine cells (control UhiPS-CMs and A561P-UhiPS CMs) at days 5, 18, and 28 of cardiac
differentiation. Quantitative reverse transcription polymerase chain reaction analysis was performed on pluripotent stem cell markers (OCT3/
4, NANOG, SOX2), on cardiomyocyte markers (NKX2-5, GJA1, GJA5, RYR2), and on key genes encoding cardiac ion channels (SCN5A,
CACNA1C, CACNA1G, KCND3, KCNQ1, KCNH2 and KCNJ2) to show enrichment for the cardiomyocyte population. The expression for each
gene and sample (n=5 per condition) was normalized to the ß-actin gene ACTB and was calculated relative to the median expression level. Raw
minimum and maximum values were taken as a reference for heat map representation. B, (top) In control UhiPS-CMs, representative
immunoﬂuorescence images of the cardiac sarcomeric protein a-actinin (green, left) and costaining of myosin light chain 2a (MLC2a; green,
middle) and myosin light chain 2v (MLC2v; red, middle) and troponin I and connexin 43 (green and red, respectively, right); (bottom) in A561P-
UhiPS CMs, representative immunoﬂuorescence images of a-actinin (red, left), costaining of MLC2a (red; middle) and MLC2v (green, middle)
and troponin I and connexin 43 (green and red, respectively, right). Scale=5 lm. CM indicates cardiomyocytes; FhiPS, foreskin ﬁbroblast–
derived human induced pluripotent stem cells; max, maximum; min, minimum; UhiPS, urine-derived human induced pluripotent stem cells.
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(Figure 3B, plot proﬁle). Further analysis of HERG protein
cellular localization was performed, combining plot proﬁle
analysis of multiple CMs differentiated from each hiPS cell
line. We found statistically signiﬁcant enrichment of HERG
protein at the membrane, compared with the intracellular
compartment, in the 2 control cell lines. In opposition, the
A561P-UhiPS CMs did not show membrane enrichment of
HERG protein (Figure 3C). These ﬁndings suggest a trafﬁcking
defect of the HERG ion channel in UhiPS-CMs carrying the
HERG A561P mutation. To further conﬁrm this result, we
investigated whether this mutation had an effect on KCNH2
gene expression. Interestingly, the A561P mutation did not
alter transcriptional expression of the KCNH2 gene (Fig-
ure S2). Using Western blot analysis, the differential expres-
sion of the immature cytosolic protein was quantiﬁed
compared with the mature plasma membrane protein (Fig-
ure S3A).24 The difference in mature over immature forms of
HERG was abolished in A561P-CMs (Figure S3B), conﬁrming a
trafﬁcking defect of mutated HERG proteins.
IKr Density Is Altered in Patient-Derived UhiPS-
CMs
Using the patch-clamp technique, we investigated whether
this trafﬁcking defect had an effect on HERG-associated
ionic current (IKr). As shown in Figure 4A and 4B, the IKr was
signiﬁcantly reduced in A561P-UhiPS CMs (P=0.007) in
comparison to control UhiPS-CMs. The tail K+ current
density measured at 50 mV was markedly reduced to
50% to 60% of the control values (Table); however, the
activation kinetics were not modiﬁed by the A561P mutation
(Figure 4C and Table). The current density reduction
observed in A561P-UhiPS CMs was consistent with the
membrane expression reduction described above (Figure 3
and Figure S3).
A561P HERG Mutation Impairs IKr Contribution to
AP in UhiPS-CMs
As expected, A561P-UhiPS CMs had statistically signiﬁcant
longer ventricular-like AP durations compared with control
UhiPS-CMs, mainly APD75 and APD90 (Figure 5A). To exclude
that the AP frequency difference was responsible for these
changes, we compared AP duration in the 2 cell groups at
comparable frequencies. To do so, we used the CellOptiq
method to record a high amount of APs at spontaneous
automatic rates. APs were then classiﬁed and compared
according to the beating frequency. The data show that in
A561P-UhiPS CMs, APD90 was signiﬁcantly longer than in
control cells regardless of the frequency and that, as expected,
the AP prolongation in A561P-UhiPS CMs was potentiated at
Figure 2. Human UhiPS cells differentiated into electrically
functional cardiomyocytes. Representative traces of sponta-
neous nodal-, atrial- and ventricular-like action potential
recordings using (A) patch-clamp or (B) optical dye (CellOptiq)
in control UhiPS-CMs and A561P-UhiPS CMs (no nodal-like AP
was obtained in A561P-UhiPS-CMs using patch-clamp tech-
nique). C, Distribution of the 3 types of action potentials
obtained by optical measurement. Regardless of the hiPS cell
type, the majority of the action potentials were ventricular-like.
Control FhiPS-CMs, n=38; control UhiPS-CMs, n=41; A561P-
UhiPS CMs, n=51. AP indicates action potential; CM, cardiomy-
ocytes; FhiPS, foreskin ﬁbroblast–derived human induced
pluripotent stem cells; UhiPS, urine-derived human induced
pluripotent stem cells.
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Figure 3. HERG trafﬁcking defect in A561P-UhiPS CMs. A, HERG protein localization (red) after
cardiac differentiation of hiPS cells, highlighting the low membrane expression of HERG in A561P-UhiPS
CMs relative to intracellular signal (magniﬁcation 920) compared with both controls (control FhiPS-CMs
and UhiPS-CMs). B, (left) Speciﬁc cellular localization of HERG (red) in cardiomyocytes with
counterstaining for troponin I (green, magniﬁcation 965); (right) surface plots of HERG staining in
each cell at the level of the line. C, Statistical analysis of surface plots of HERG ﬂuorescence intensity
signal. Control FhiPS-CMs, n=12; control UhiPS-CMs, n=12; A561P-UhiPS CMs, n=20. The surface plot
was arbitrarily segmented in 3 different areas: the ﬁrst and last 15% of the surface plot, corresponding to
plasma membrane (M1 and M2, as described in Figure 3B), and the remaining intermediate 70% of the
surface plot, corresponding to the intracellular compartments. For each of these areas in each cell, the
HERG ﬂuorescence intensity values were averaged and normalized to the average cell HERG
ﬂuorescence intensity signal. Paired t tests were performed between membrane and intracellular
signals. ***P<0.001, for membrane vs intracellular ﬂuorescence intensity signal. CM indicates
cardiomyocytes; FhiPS, foreskin ﬁbroblast–derived human induced pluripotent stem cells; I, intracellular
compartments; UhiPS, urine-derived human induced pluripotent stem cells.
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slower rates25 (Figure 5B). In addition, statistical analyses with
2-way ANOVA show that the effect of the frequency on APDs
was minor compared with the effect of the HERG mutation.
Consequently, the APD prolongation observed in our LQT2
model likely was mainly due to the mutation. These data show
that UhiPS-CMs model the typical AP prolongation associated
with LQT2 syndrome.
UhiPS-CMs Carrying the HERG A561P Mutation
Have Increased Susceptibility to Arrhythmia
The HERG A561P mutation carrier experienced arrhythmic
episodes (ie, torsades de pointes) when treated with the
HERG channel blocker clobutinol. Because this drug is no
longer available, we used the HERG blocker E-4031 to
evaluate susceptibility to arrhythmia in control and A561P-
UhiPS CMs. E-4031 did not trigger any arrhythmic event in
control UhiPS-CMs recorded with the CellOptiq method
(n=10), but an arrhythmic event was recorded in 1 A561P-
UhiPS CM of 6 cells upon E-4031 treatment. Ventricular-like
APs recorded with the patch-clamp technique exhibited
Figure 4. Reduction of delayed rectiﬁer K+ current (IKr) density in A561P-UhiPS CMs. A, Representative raw data of currents recorded from
control UhiPS-CMs (left) and A561P-UhiPS-CMs (right); protocol is shown as inset (holding potential: 50 mV; stimulation frequency: 1/
12.5 Hz; traces with test pulse from 40 to 0 mV are shown). Currents are shown before and after 1 lmol/L E-4031 application. E-4031-
sensitive currents are considered as IKr. B, Tail current density measurement obtained on repolarization after test pulse at +60 mV in control
UhiPS-CMs (n=13) and A561P-UhiPS CMs (n=11), highlighting a signiﬁcant reduction in A561P-UhiPS CMs. Protocol is shown in inset. **P<0.01
vs control UhiPS-CMs. C, Voltage-dependent activation curves obtained by plotting the relative E-4031-sensitive current on repolarization at
50 mV (arrows in A) in control UhiPS-CMs (n=13) and A561P-UhiPS CMs (n=8) (arrows in A). CM indicates cardiomyocytes; Ctrl, control;
UhiPS, urine-derived human induced pluripotent stem cells.
Table. Effects of A561P Mutation on Delayed Rectiﬁer K+
Current in UhiPS-CMs
Control UhiPS-CMs A561P-UhiPS CMs
Tail current density
(n)
1.790.2 pA/pF
(13)
0.890.1 pA/pF**
(11)
Activation
V1/2 26.491.7 mV 23.811.5 mV
k
(n)
7.750.7 mV
(13)
7.10.7 mV
(8)
The tail current density was measured at50 mV following a depolarization to +60 mV.
CMs indicates cardiomyocytes; k, slope factor (see protocol in Figure 4A); pA, current
amplitude; pF, cellmembrane capacitance; UhiPS, urine-derivedhuman induced pluripotent
stem cells; V1/2, prepulse voltage for which the tail current is half of its maximal value.
**P<0.01 vs control UhiPS-CMs.
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spontaneous Early after-depolarizations (EADs) only in A561P-
UiPS CMs (in 2 of 7 cells). As shown in Figure 5C, EADs were
exacerbated in the presence of E-4031, a reﬂection of the
patient’s phenotype, which was characterized by arrhythmias
when treated with the antitussive drug clobutinol. Quantitative
analysis of the prolongation of APD50, APD75, and APD90
showed statically signiﬁcant prolongation of APD75 and APD90
in both control and A561P-UhiPS CMs, with, as expected,
greater prolongation in the mutated cells (Figure 5D).
Discussion
In the present study, we demonstrated that the use of patient-
speciﬁc iPS cells obtained from urine samples is a powerful
approach to modeling the subtlety of human cardiac arrhyth-
mic disease in vitro. The cells were differentiated into
functional CMs that reproduced both phenotypic character-
istics of this LQT2 mutation, namely, (1) prolonged repolar-
ization and (2) increased drug-induced arrhythmogenicity.
Figure 5. Action potentials recorded from A561P-UhiPS CMs model type 2 long QT syndrome. A, Ventricular-like APDs using patch-clamp (left,
n=7 in each group) and optical measurement (right, n=27 and 30 for control and A561P cells, respectively). B, APD90 at 2 different AP
frequencies, showing a larger prolongation in A561P-UhiPS CMs at slow rate (white circles) compared with control UhiPS-CMs (black circles;
n=13 and 6 for control and A561P cells, respectively). Statistical signiﬁcance: *P<0.05, **P<0.01, ***P<0.001, for A561P-UhiPS CMs vs
control UhiPS-CMs. C, Increased arrhythmia susceptibility in A561P-UhiPS CMs in the presence of E-4031: representative action potential
patch-clamp recordings before and after 1 lmol/L E-4031 treatment. D, Quantiﬁcation of the prolongation of the APD after E-4031 treatment of
control UhiPS-CMs (gray bars) and A561P-UhiPS CMs (white bars). Statistical signiﬁcance of APD prolongation after E-4031 treatment in each
cell type: *P<0.05. AP indicates action potential; APD, action potential duration; CM, cardiomyocytes; UhiPS, urine-derived human induced
pluripotent stem cells.
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The opportunity of producing unique patient- and disease-
speciﬁc hiPS cell lines7,26,27 provides genetically deﬁned
cellular human models for studying diseases, taking in
consideration the patient’s speciﬁc genetic background. This
approach has been applied successfully to cardiac arrhythmic
diseases28, including LQT2 syndrome29–32, in which hiPS cell
lines were derived from dermal ﬁbroblasts; however, owing to
the complications associated with skin biopsy collection, in all
these studies, control hiPS cells were derived from genetically
unrelated persons30–32 or even from human embryonic stem
cell–derived ﬁbroblasts and thus had a different genetic
context.29 Nevertheless, direct reprogramming of somatic
cells into pluripotent cells should address the need to study
patient-speciﬁc cells as well as cells derived from control
subjects, of any age and, ideally, from family relatives. This
would allow testing of the speciﬁc role of a mutation in a
pathological phenotype by comparing phenotypes in similar
genetic backgrounds.
To avoid skin biopsy—an invasive procedure that raises
ethical issues when collected from young persons or healthy
relatives—less invasive methods are required. Recently, Zhou
et al.3 were able to reprogram urine-derived cells, collected
using a completely noninvasive method, into iPS cells. Our
study shows that these cells can be differentiated into CMs
and used to model an arrhythmic cardiac disease. There are,
however, some limitations. First, in our laboratory, 79 urine
samples were collected from the same number of persons for
several ongoing studies. Using both penicillin and strepto-
mycin in culture medium at usual concentrations, 8 samples
were contaminated (data not shown). Cells from urine
samples were isolated and expanded from only 45 (57%)
donors. These results are comparable to those obtained by
one of the ﬁrst studies using urine cells to generate iPS cells.3
Nevertheless, the fact that cells cannot be obtained from all
urine samples is an important limitation in comparison to
peripheral blood mononuclear cells, which can usually be
obtained from any participant. Consequently, if no urine cells
can be isolated from urine samples of donors, either more
urine samples must be harvested and cultivated or the use of
peripheral blood mononuclear cells or skin biopsy may be
necessary. Second, no “quarantine” time was necessary to
eliminate contaminated samples, but usually 2 to 3 weeks
were needed to obtain a sufﬁcient number of cells for
reprogramming. This culture duration is usual with ﬁbroblasts
from skin biopsies but is a limitation in comparison to
peripheral blood mononuclear cells, which can be used
immediately after puriﬁcation; however, urine samples are
easy to obtain from any participant, including intrafamilial
controls and pediatric patients. Consequently, the use of urine
samples may be a good starting point to obtain iPS cells,
followed by blood harvesting in case of lack of urine cells.
Finally, the study was performed with only 1 patient and 2
controls. Similar investigations with other patients with other
HERG mutations would be useful to conﬁrm the strength of
this new model.
Intense research efforts have been directed at developing
methods to differentiate CMs from hiPS cells by mimicking
the cell-signaling environment during the early stages of
cardiogenesis. We chose to use the matrix sandwich method,
one of the most recently designed protocols, which has been
reported to have among the highest efﬁcacy for differentia-
tion16; however, differentiation efﬁcacy can be speciﬁc to iPS
cell line. This method, for example, has been unsuccessful at
differentiating cord blood–derived iPS cells as opposed to skin
ﬁbroblast–derived iPS cells due to their parental source
memory.33 We tested whether this method would be efﬁcient
at differentiating urine-derived iPS cells. In this study, we
showed that urine cells reprogrammed with nonintegrating
episomal vectors can be differentiated into CMs from a
monolayer cell culture using the matrix sandwich method.
To validate the use of urine-derived iPS cells for modeling
cardiac arrhythmic disease, we selected a mild form of LQT2
syndrome, related to HERG, because the LQT2 syndrome is
the reference model in studies using conventional skin
ﬁbroblast–derived iPS cells. Before the use of iPS cells,
studies of HERG channel mutations, as for other channels,
were conducted in heterologous expression systems, provid-
ing insights into the probable mechanism of LQT2. Those
studies showed that defects in expression, trafﬁcking, and/or
function of the mutated channels can be responsible for the
diseased phenotype; however, these systems hampered the
complete understanding of this disease mechanism. Indeed,
they are noncardiac cell types that do not provide a fully
integrated vision, and some of the disease phenotypes cannot
be investigated using these systems, forcing investigators to
resort to noncellular methods such as mathematical modeling
of AP.
The studied patient presented QT prolongation (corrected
QT interval 597 ms) and was asymptomatic until he
experienced syncope and torsades de pointes arrhythmias
during treatment with clobutinol, a common antitussive
drug.14 It has been proposed that the population prevalence
of milder long QT syndrome mutations might be high,34 and
it is now recognized that such form of long QT syndrome
could manifest itself as a predisposition to drug-induced
torsades de pointes, as in the case of the patient with the
A561P mutation presented in this study. In addition, it has
been demonstrated by Moss et al.35 that mutations in
different locations of the HERG potassium-channel gene are
associated with different levels of risk for arrhythmic cardiac
events in LQT2, which makes it important to focus on mild
phenotypes and to discern them from severe phenotypes.
Interestingly, this study demonstrates that the use of urine-
derived iPS cell models allows replication of the subtlety of a
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patient-speciﬁc phenotype, a result that widens the useful-
ness of iPS cells to model arrhythmogenic syndromes with
complex phenotypes.
The A561P mutation has been the subject of a previous
study conducted in the laboratory using transfected COS-7
cells.14 This study showed that the A561P mutation induced
defects in HERG trafﬁcking and biophysical properties.
Because of the lack of a cardiac cellular model, its impact
on AP duration had been tested using computer simula-
tions.14 In the present study, we investigated the mutation-
associated disease mechanism in human CMs differentiated
from UhiPS cells carrying the HERG A561P mutation in
comparison to 2 controls, 1 of which was UhiPS-CMs
generated from a healthy family member (mother). The
second control was derived from foreskin ﬁbroblasts of a
healthy person.15 Almost all studies that investigated the
mutations associated with arrhythmic diseases in hiPS-CMs
recognized that those cells are immature, with electrical
properties similar to fetal or neonatal CMs; however, our
results showed that these cells were capable of capturing
speciﬁc traits of LQT2 syndrome, namely, reduced IKr
amplitude leading to prolongation of AP. A discrepancy
between the present study and our former study is that we did
not conﬁrm that the HERG A561P mutation results in
modiﬁcation of the voltage dependence of activation, as
described in COS-7 cells.14 In COS-7 cells, this phenotype
was probably due to the speciﬁc protein environment of the
exogenous channel in COS-7 that may exacerbate subtle
differences that do not exist in the native environment.
Our data further support the use of CMs differentiated
from iPS cells rather than noncardiac heterologous expression
systems for providing genuine knowledge of the mechanism
for cardiac channelopathies. To date, they are the closest
model to human CMs sourced directly from cardiac tissue,
providing accurate insights into the molecular basis of disease
phenotypes. Moreover, we demonstrated that iPS cells
derived from a urine sample are an alternative strategy for
cardiac arrhythmic disease modeling, with the advantage of
facilitating the study of familial controls compared with more
invasive ﬁbroblast collection procedures, broadening the
potential for iPS cell–guided personalized medicine.
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Supplemental Figure 1: Characterization of hiPS cells from urine samples (UhiPS). (A) 
Endogenous pluripotent stem cell marker (OCT3/4 and TRA1-60) visualization by 
immunofluorescence staining of one Control UhiPS clones and two A561P-UhiPS clones. (B) 
Expression level of additional endogenous pluripotent stem cell marker (OCT3/4, NANOG and SOX2) 
genes by qRT-PCR in control and A561P-UhiPS cells as compared to their corresponding urine cells, 
and expression level of the episomal vector in the same hiPS clones, at passage 10. (C) Percentage of 
control and A561P-UhiPS cells expressing the pluripotency genes SSEA4, SSEA3 and TRA1-60 
measured by flow cytometry. (D) Teratoma formation following injection of undifferentiated UhiPS 
cells in NOD/SCID mice. The presence of neural tissue (ectoderm, top), intestinal epithelium 
(endoderm, middle) and immature bone tissue and cartilage (mesoderm, bottom) is shown. 
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Supplemental Tables 
 
Supplemental Table 1. TaqMan probes and SYBR Green primers. Applied Biosystems references 
and gene names are listed. 
TaqMan Probes 
Gene Reference 
ACTB Hs99999903_m1 
SOX2 Hs01053049_s1 
NANOG Hs02387400_g1 
POU5F1 Hs04260367_g1 
NKX2-5 Hs00231763-m1 
GJA1 Hs00748445_s1 
GJA5 Hs00270952_s1 
RYR2 Hs00892883_m1 
KCNJ2 Hs00265315_m1 
KCNQ1 Hs00923522-m1 
KCNH2 Hs04234270-g1 
KCND3 Hs00542597_m1 
CACNA1C Hs00167681_m1 
CACNA1G Hs00367969_m1 
SCN5A Hs00165693_m1 
Episomal detection primers 
Orientation Sequence 
Forward GGCTCTCCCATGCATTCAAA 
Reverse GGCCCTCACATTGCCAAA 
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